Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03837899 · ClinicalTrials.gov registry record · Phase 1
Durvalumab and Tremelimumab for Pediatric Malignancies
A Phase 1 study of Pediatric Cancer and Hematological Malignancies, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 19
- Study locations
NCT03837899: Active Phase 1 study of Pediatric Cancer and Hematological Malignancies, sponsored by AstraZeneca.
NCT03837899 is a Phase 1 study of Pediatric Cancer and Hematological Malignancies that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 50 participants, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower). The trial reports 19 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03837899, a Phase 1 study of Pediatric Cancer and Hematological Malignancies, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.
Primary Outcome
Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.
Conditions Studied
Interventions
- DRUG Durvalumab / Tremelimumab Combination Therapy
Study Locations (19)
Other
- Research Site - Lille
- Research Site - Marseille
- Research Site - Paris
- Research Site - Cologne
- Research Site - Genova
- Research Site - Milan
- Research Site - Rome
- Research Site - Torino
- Research Site - Utrecht
- Research Site - Barcelona
- Research Site - Madrid
- Research Site - Leeds
- Research Site - London
- Research Site - Sutton
Maryland
- Research Site - Baltimore
Massachusetts
- Research Site - Boston
New York
- Research Site - New Hyde Park
Oklahoma
- Research Site - Oklahoma City
South Carolina
- Research Site - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
What the registry record for NCT03837899 still lists
NCT03837899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab / Tremelimumab Combination Therapy is the first listed.
NCT03837899 lists 19 locations in 6 states (Other, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03837899 about?
NCT03837899 is a clinical study titled "Durvalumab and Tremelimumab for Pediatric Malignancies". The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.
What is the current status of trial NCT03837899?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2019-03-07. Estimated completion is 2024-12-30.
What conditions does trial NCT03837899 study?
This clinical trial studies the following conditions: Pediatric Cancer, Hematological Malignancies, Solid Tumor Pediatric.
What interventions are being tested in trial NCT03837899?
The interventions under investigation include: Durvalumab / Tremelimumab Combination Therapy (DRUG).
Who is sponsoring clinical trial NCT03837899?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03837899 being conducted?
This trial has 19 study locations across Maryland, Massachusetts, New York, Oklahoma, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03837899's enrollment target sits among peer trials
50 29th of 51 higher than 22 of 51 other Pediatric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Lurbinectedin in FET-Fused Tumors
RECRUITING · Phase 1
-
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
COMPLETED · Phase 1
-
LIFE Cancer Survivorship Database for Pediatric Cancer
RECRUITING
-
Multisite Implementation of COMPRENDO
RECRUITING · NA
-
Childhood Cancer Predisposition Study (CCPS)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI